Virpax Pharmaceuticals, Inc. financial data

Symbol
VRPX on Nasdaq
Location
1055 Westlakes Drive, Suite 300, Berwyn, PA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 119 % -78.3%
Debt-to-equity 541 % +2310%
Return On Equity -78.3 % -23%
Return On Assets -243 % -209%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 4.89M shares -58.3%
Common Stock, Shares, Outstanding 2.84M shares -75.8%
Entity Public Float 9.4M USD -35.7%
Common Stock, Value, Issued 28 USD -76.1%
Weighted Average Number of Shares Outstanding, Basic 1.98M shares +68.8%
Weighted Average Number of Shares Outstanding, Diluted 1.98M shares +68.8%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 6.16M USD -7.9%
General and Administrative Expense 11.4M USD +26.4%
Operating Income (Loss) -17.6M USD -11.8%
Nonoperating Income (Expense) 8.13K USD -93.6%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -16.9M USD +6.35%
Net Income (Loss) Attributable to Parent -17.2M USD -12.9%
Earnings Per Share, Basic -13.5 USD/shares +37.2%
Earnings Per Share, Diluted -13.5 USD/shares +37.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Assets, Current 2.59M USD -83.8%
Assets 2.59M USD -83.8%
Liabilities, Current 5.39M USD +47.7%
Liabilities 5.39M USD +47.7%
Retained Earnings (Accumulated Deficit) -66.2M USD -35.2%
Stockholders' Equity Attributable to Parent -2.79M USD -123%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 19.4M USD -53.1%
Liabilities and Equity 2.59M USD -83.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -7.73M USD -285%
Net Cash Provided by (Used in) Financing Activities 454K USD
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 2.84M shares -75.8%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 1.87M USD -87.4%
Deferred Tax Assets, Valuation Allowance 15.9M USD +19.6%
Deferred Tax Assets, Gross 15.9M USD +19.6%
Deferred Tax Assets, Operating Loss Carryforwards 8.85M USD +7.9%
Preferred Stock, Shares Authorized 10M shares 0%
Additional Paid in Capital 63.4M USD +3.47%
Deferred Tax Assets, Net of Valuation Allowance 6.62M USD +91.4%
Share-based Payment Arrangement, Expense 72.5K USD -66.8%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%